LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
Year: 2022
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: The Lancet
Institutions: Eli Lilly (United States), Duke University, Duke Medical Center
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4307648695
